Temporal changes of serum cytokine/chemokine levels in patients of Nakajo-Nishimra syndrome treated with tocilizumab by unknown
POSTER PRESENTATION Open Access
Temporal changes of serum cytokine/chemokine
levels in patients of Nakajo-Nishimra syndrome
treated with tocilizumab
N Kanazawa1*, Y Nakatani1, Y Inaba1, K Kunimoto1, F Furukawa1, F Ozaki2
From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
Dresden, Germany. 30 September - 3 October 2015
In Nakajo-Nishimura syndrome (NNS), proteasome dis-
ability due to a loss-of-function PSMB8 mutation
induces storage of ubiquitinated proteins and overpro-
duction of inflammatory cytokines and chemokines.
However, the precise mechanisms causing complex phe-
notypes of the disease, including pernio-like eruptions,
lipodystrophy and calcification of basal ganglia, is mostly
unclear. As IL-6 overproduction in association with p38
hyperactivation was supposed to have a role in NNS
(Arima et al, PNAS 2011), tocilizumab, a monoclonal
antibody for IL-6 receptor, has recently been applied for
two patients with NNS after informed consents were
obtained. Decreased serum CRP and CPK levels in both
patients and improved myalgia and arthralgia in one
patient have been observed, whereas none of decrease in
serum LDH level or improvement of fever and eruptions
have been achieved. By analysis of serum cytokine/
chemokine levels, IL-6, G-CSF and MCP-1 levels have
changed in accordance to the CRP level, whereas IP-10
has shown constantly high levels independent of the
CRP level. Furthermore, both the patients-derived per-
ipheral blood monocytes and monocytes differentiated
from a patient-derived iPS cells produced higher level of
IP-10 than control cells after IFNgamma stimulation.
These findings suggest that monocyte-derived IP-10 has
a major role in pathogenesis of the sustained/progres-
sing phenotypes in NNS.
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